Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study - PubMed

4 days ago

Qualitative exit interviews were conducted with participants from the SURMOUNT-OSA phase III trials to explore their experiences with obstructive sleep apnea (OSA) and tirzepatide treatment.
Participants reported the 'worst' OSA symptoms as snoring and temporary breath cessation, with sleep-related impairment and disturbance being the most impactful.
Tirzepatide-treated participants showed greater improvements in OSA symptoms, sleep quality, and daytime functioning compared to placebo-treated participants.
Treatment satisfaction was higher among tirzepatide-treated participants, with ease of administration, weight reduction, and symptom improvement being the most liked aspects.
The study highlights the positive effects of tirzepatide in managing OSA symptoms and improving quality of life for patients with obesity and moderate-to-severe OSA.

Hasty Briefsbeta